Last reviewed · How we verify

NCT06236841

A Phase I Study of XH-S004 in Healthy Volunteers

Status unknown Phase 1 Last updated 5 February 2024
What this trial tests

Phase 1 trial testing XH-S004 tablet in Healthy Adults in 90 participants. Status unknown.

Timeline
26 January 2024
Primary endpoint
31 January 2025
31 January 2025

Quick facts

Lead sponsorS-INFINITY Pharmaceuticals Co., Ltd
PhasePhase 1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment90
Start date26 January 2024
Primary completion31 January 2025
Estimated completion31 January 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

S-INFINITY Pharmaceuticals Co., Ltd — full company profile →

Who can join

Adults 18 to 45, any sex, with Healthy Adults. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase I, randomised, double-blind placebo-controlled, 3-part study to assess the safety, tolerability, pharmacokinetics and food effect of single and multiple oral doses of XH-S004 in healthy volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Healthy Adults

Currently open trials in the same condition.

Other S-INFINITY Pharmaceuticals Co., Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06236841.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing